page contents

Depression and the Childhood Depression Inventory

Depression and the Childhood Depression Inventory Presented at the American Academy of Child and Adolescent Psychiatry, 2004 Annual Meeting C Petersen, M.D., Department of Psychiatry, Penn State College of Medicine; , S Mayes, Ph.D., N Vegesna, M.D., D Mauger, Ph.D. Abstract Objective:  This study on inpatient children reports on the congruence of a clinician’s DSM-IV diagnosis versus a patient-administered scale (CDI) versus the parent’s report of depression. Methods: The sample comprised 111 children, 5 to 15 years of age admitted to our child psychiatry unit. Sixty-three of the children had a DSM-IV diagnosis of depression and 48 did not. Children completed the CDI. Results: CDI scores differed significantly (p < .0001) between children with depression and children without depression. Positive and negative predictive power were high (79% and 61%). Within the depressed group, percent agreement for depression was 81% for the child psychiatrist and child, and 81% for the psychiatrist and parent. Conclusion:  The CDI is a valuable instrument in the inpatient assessment of children and is a good predictor of depressive diagnosis. See full report in PDF format Free Adobe Acrobat Reader 5.0 to download and read the above PDF file (If you have an earlier version please upgrade to 5.0 for... Resource

Coalition Launches “Helping Parents Help Their Kids” Tuesday, Feb. 1, 2005 Washington, D.C. – Today a large coalition of medical and family/patient advocacy organizations launched, a new resource center for parents of children and adolescents with depression. A focal point of the Web site is a fact sheet called “The Use of Medication in Treating Childhood and Adolescent Depression: Information for Patients and Families” – practical advice for parents that has been endorsed by more than a dozen national organizations, including: • American Academy of Child and Adolescent Psychiatry • American Psychiatric Association The guides and the site will be updated on an ongoing basis with the latest scientific and medical research. They are being launched as new data suggest the number of children receiving treatment that includes antidepressant medication continues to decline. “The evidence clearly suggests that the FDA’s action regarding the black box warning is already having a dramatic effect on prescribing patterns across the country,” said Dr. Fassler. “As a result, many children are losing access to effective and appropriate treatment.” The coalition convened for the first time in November 2004 as a work group sponsored by the American Psychiatric Association and the American Academy of Child and Adolescent Psychiatry. The Parent Guide can be found on the Web at The Physician Guide is at...

FDA and Antidepressants in Children

FDA Statement on Recommendations of the Psychopharmacologic Drugs and Pediatric Advisory Committees September 16, 2004 – The Food and Drug Administration (FDA) generally supports the recommendations that were recently made to the agency by the Psychopharmacologic Drugs and Pediatric Advisory Committees regarding reports of an increased risk of suicidality (suicidal thoughts and actions) associated with the use of certain antidepressants in pediatric patients. FDA has begun working expeditiously to adopt new labeling to enhance the warnings associated with the use of antidepressants and to bolster the information provided to patients when these drugs are dispensed. In summary, the members of the advisory committees: endorsed FDA’s approach to classifying and analyzing the suicidal events and behaviors observed in controlled clinical trials and expressed their view that the new analyses increased their confidence in the results; concluded that the finding of an increased risk of suicidality in pediatric patients applied to all the drugs studied (Prozac, Zoloft, Remeron, Paxil, Effexor, Celexa Wellbutrin, Luvox and Serzone) in controlled clinical trials; recommended that any warning related to an increased risk of suicidality in pediatric patients should be applied to all antidepressant drugs, including those that have not been studied in controlled clinical trials in pediatric patients, since the available data are not adequate to exclude any single medication from an increased risk; reached a split decision (15-yes, 8-no) regarding recommending a “black-box” warning related to an increased risk for suicidality in pediatric patients for all antidepressant drugs; endorsed a patient information sheet (“Medication Guide”) for this class of drugs to be provided to the patient or their caregiver with every prescription; recommended that...
Page 1 of 212